Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Audio By Carbonatix

HOUSTON--(BUSINESS WIRE)--Nov 18, 2025--

Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the company’s management will participate in a fireside chat and host investor one-on-one investor meetings at the Piper Sandler 37 th Annual Healthcare Conference, being held December 2-4, 2025 in New York, NY.

Details are as follows:

Piper Sandler 37 th Annual Healthcare Conference
Format: Fireside Chat
Date: Tuesday, December 2, 2025
Time: 12:00 PM ET

The webcast of the fireside chat will be accessible on the Tvardi Investors’ website. A replay of the webcast will be available for approximately 90 days following the conference.

About Tvardi Therapeutics

Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The company is conducting clinical trials with TTI-101 in hepatocellular carcinoma (NCT05440708) and TTI-109 in healthy volunteers. To learn more, please visit tvarditherapeutics.com or follow us on LinkedIn and X (Twitter).

View source version on businesswire.com:https://www.businesswire.com/news/home/20251118355835/en/

CONTACT: For Tvardi:

Tvardi Investor Relations

[email protected] Kelleher

LifeSci Advisors

617-430-7579

[email protected]

KEYWORD: TEXAS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH ONCOLOGY

SOURCE: Tvardi Therapeutics, Inc.

Copyright Business Wire 2025.

PUB: 11/18/2025 08:00 AM/DISC: 11/18/2025 08:00 AM

http://www.businesswire.com/news/home/20251118355835/en